Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex IBW Dosing in Morbid Obesity
NCT02545595Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- May 2012
- Primary completion
- Dec 2013
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by CHU de Poitiers. Started May 2012; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02545595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545595.